Quebec City, Quebec, April 11, 2023 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced the successful completion of enrollment in the SAFE‑TAVI clinical study, studying left ventricular rapid pacing using SavvyWire in transcatheter aortic valve implantation procedures (TAVI or TAVR), in Europe. The study enrolled 120 patients with severe aortic valve stenosis and other conditions requiring a TAVI procedure in which left ventricular rapid pacing was considered necessary.